DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Up 0.0 %

DURECT stock opened at $0.84 on Wednesday. The company has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $1.21. DURECT has a 1-year low of $0.68 and a 1-year high of $1.88. The company has a market cap of $26.08 million, a P/E ratio of -1.38 and a beta of 0.94.

Hedge Funds Weigh In On DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC lifted its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 319,905 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,658 shares during the quarter. Geode Capital Management LLC owned approximately 1.03% of DURECT worth $429,000 as of its most recent SEC filing. 28.03% of the stock is owned by institutional investors and hedge funds.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.